We advised Mirxes on its IPO and HKEX listing

Davis Polk advised Mirxes in connection with its initial public offering and listing on the Hong Kong Stock Exchange. The gross proceeds from the offering amounted to approximately HK$1.09 billion.

Mirxes is a micro ribonucleic acid (miRNA) technology company headquartered in Singapore, making diagnostic solutions for the screening of diseases accessible across the key markets in Asia, including Singapore and China. Its core product, GASTROClear, is the first and only approved molecular IVD product for gastric cancer screening globally. The offering was conducted in reliance on Regulation S.

The Davis Polk corporate team included partners Xuelin (Steve) Wang, Jason Xu and James C. Lin, counsel Wendy Kan, registered foreign lawyer Eva Xu and associates Sarah Shi and Ching Suen. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.

Copy link to share post